Response to hepatitis B vaccination in patients with liver cirrhosis

Reviews in Medical Virology

Volumn 27, Issue 6, 2017, Pages

  Aggeletopoulou, Ioanna ^a   Davoulou, Panagiota ^a   Konstantakis, Christos ^a   Thomopoulos, Konstantinos ^a   Triantos, Christos ^a  

^a UNIVERSITY HOSPITAL OF PATRAS   (Greece)

Author keywords

hepatitis B vaccine; immune response; liver cirrhosis

Indexed keywords

RECOMBINANT HEPATITIS B VACCINE; HEPATITIS B VACCINE;

DRUG SAFETY; HEPATITIS B; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; LIVER CIRRHOSIS; MEDLINE; REVIEW; SYSTEMATIC REVIEW; TREATMENT RESPONSE; VACCINATION; EPIDEMIOLOGY; HEPATITIS B VIRUS; IMMUNIZATION; IMMUNOLOGY; META ANALYSIS; OUTCOME ASSESSMENT; VACCINE IMMUNOGENICITY;

CONFOUNDING FACTORS (EPIDEMIOLOGY); HEPATITIS B; HEPATITIS B VACCINES; HEPATITIS B VIRUS; HUMANS; IMMUNIZATION SCHEDULE; IMMUNOGENICITY, VACCINE; LIVER CIRRHOSIS; PATIENT OUTCOME ASSESSMENT; VACCINATION;

EID: 85034611866     PISSN: 10529276     EISSN: 10991654     Source Type: Journal    
DOI: 10.1002/rmv.1942     Document Type: Review

References (64)

1. Trépo C, Chan HL, Lok A. Hepatitis B virus infection. The Lancet. 2014;384:2053-2063.
2. WHO. Hepatitis B. http://www.who.int/mediacentre/factsheets/fs204/en. 2015.
3. Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet. 2015;386:1546-1555. https://doi.org/10.1016/s0140-6736(15)61412-x
4. El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 2012;142:1264-1273. e1261. https://doi.org/10.1053/j.gastro.2011.12.061
5. Lernout T, Hendrickx G, Vorsters A, Mosina L, Emiroglu N, Van Damme P. A cohesive European policy for hepatitis B vaccination, are we there yet? Clin Microbiol Infect. 2014;20:19-24. https://doi.org/10.1111/1469-0691.12535
6. Mast EE, Margolis HS, Fiore AE, et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States. MMWR. 2005;54:1-32.
7. Centers for Disease Control and Prevention. Hepatitis B FAQs for health professionals. 2012.
8. Mast EE, Weinbaum CM, Fiore AE, et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) part II: immunization of adults. MMWR Recomm Rep. 2006;55:1-33. quiz CE31-34.
9. Centers for Disease Control and Prevention. Epidemiology and prevention of vaccine-preventable diseases. Washington DC: Public Health Foundation 2011; 12.
10. Leuridan E, Van Damme P. Hepatitis B and the need for a booster dose. Clin Infect Dis. 2011;53:68-75. https://doi.org/10.1093/cid/cir270
11. Venters C, Graham W, Cassidy W. Recombivax-HB: perspectives past, present and future. Expert Rev Vaccines. 2004;3:119-129. https://doi.org/10.1586/14760584.3.4.S119
12. Hussain Z, Ali SS, Husain SA, Raish M, Sharma DR, Kar P. Evaluation of immunogenicity and reactogenicity of recombinant DNA hepatitis B vaccine produced in India. World J Gastroenterol. 2005;11:7165-7168.
13. Said ZNA, Abdelwahab KS. Induced immunity against hepatitis B virus. World J Hepatol. 2015;7:1660-1670. https://doi.org/10.4254/wjh.v7.i12.1660
14. Wiedermann U, Garner-Spitzer E, Wagner A. Primary vaccine failure to routine vaccines: why and what to do? Hum Vaccin Immunother. 2016;12:239-243.
15. Chalasani N, Smallwood G, Halcomb J, Fried MW, Boyer TD. Is vaccination against hepatitis B infection indicated in patients waiting for or after orthotopic liver transplantation? Liver Transpl Surg. 1998;4:128-132.
16. Engler SH, Sauer PW, Golling M, et al. Immunogenicity of two accelerated hepatitis B vaccination protocols in liver transplant candidates. Eur J Gastroenterol Hepatol. 2001;13:363-367.
17. Kallinowski B, Benz C, Buchholz L, Stremmel W. Accelerated schedule of hepatitis B vaccination in liver transplant candidates. Transplant Proc. 1998;30:797-799.
18. Roni DA, Pathapati RM, Kumar AS, Nihal L, Sridhar K, Tumkur Rajashekar S. Safety and efficacy of hepatitis B vaccination in cirrhosis of liver. Adv Virol. 2013;2013: 196704. https://doi.org/10.1155/2013/196704
19. Villeneuve E, Vincelette J, Villeneuve JP. Ineffectiveness of hepatitis B vaccination in cirrhotic patients waiting for liver transplantation. Can J Gastroenterol. 2000;14: Suppl B: 59b-62b
20. Angelico M, Di Paolo D, Trinito MO, et al. Failure of a reinforced triple course of hepatitis B vaccination in patients transplanted for HBV-related cirrhosis. Hepatology. 2002;35:176-181. https://doi.org/10.1053/jhep.2002.30278
21. Arslan M, Wiesner RH, Sievers C, Egan K, Zein NN. Double-dose accelerated hepatitis B vaccine in patients with end-stage liver disease. Liver Transpl. 2001;7:314-320. https://doi.org/10.1053/jlts.2001.23069
22. Bonazzi PR, Bacchella T, Freitas AC, et al. Double-dose hepatitis B vaccination in cirrhotic patients on a liver transplant waiting list. Braz J Infect Dis. 2008;12:306-309.
23. Carey W, Pimentel R, Westveer MK, Vogt D, Broughan T. Failure of hepatitis B immunization in liver transplant recipients: results of a prospective trial. Am J Gastroenterol. 1990;85:1590-1592.
24. de Artaza VT, Sanchez Ruano JJ, Garcia Vela A, et al. Efficacy and safety of vaccination against hepatitis A and B in patients with chronic liver disease. Gastroenterol Hepatol. 2009;32:483-488. https://doi.org/10.1016/j.gastrohep.2009.03.009
25. Di Paolo D, Lenci I, Cerocchi C, et al. One-year vaccination against hepatitis B virus with a MPL-vaccine in liver transplant patients for HBV-related cirrhosis. Transpl Int. 2010;23:1105-1112. https://doi.org/10.1111/j.1432-2277.2010.01104.x
26. Dominguez M, Barcena R, Garcia M, Lopez-Sanroman A, Nuno J. Vaccination against hepatitis B virus in cirrhotic patients on liver transplant waiting list. Liver Transpl. 2000;6:440-442. https://doi.org/10.1053/jlts.2000.8313
27. Gutierrez Domingo I, Pascasio Acevedo JM, Alcalde Vargas A, et al. Response to vaccination against hepatitis B virus with a schedule of four 40-mug doses in cirrhotic patients evaluated for liver transplantation: factors associated with a response. Transplant Proc. 2012;44:1499-1501. https://doi.org/10.1016/j.transproceed.2012.05.071
28. Horlander JC, Boyle N, Manam R, et al. Vaccination against hepatitis B in patients with chronic liver disease awaiting liver transplantation. Am J Med Sci. 1999;318:304-307.
29. Jilg W, Schmidt M, Deinhardt F. Four-year experience with a recombinant hepatitis B vaccine. Infection. 1989;17:70-76.
30. Macedo G, Maia JC, Gomes A, Teixeira A, Ribeiro T. Efficacy of a reinforced protocol of HBV vaccination in cirrhotic patients waiting for orthotopic liver transplantation. Transplant Proc. 2000;32:2641.
31. Mendenhall C, Roselle GA, Lybecker LA, et al. Hepatitis B vaccination: response of alcoholic with and without liver injury. Dig Dis Sci. 1988;33:263-269.
32. Van Thiel DH, el-Ashmawy L, Love K, Gavaler JS, Starzl TE. Response to hepatitis B vaccination by liver transplant candidates. Dig Dis Sci. 1992;37:1245-1249.
33. Publication W. Hepatitis B vaccines: WHO position paper—recommendations. Vaccine. 2010;28:589-590.
34. Walayat S, Ahmed Z, Martin D, Puli S, Cashman M, Dhillon S. Recent advances in vaccination of non-responders to standard dose hepatitis B virus vaccine. World J Hepatol. 2015;7:2503-2509. https://doi.org/10.4254/wjh.v7.i24.2503
35. Vora KA, Tumas-Brundage K, Manser T. Contrasting the in situ behavior of a memory B cell clone during primary and secondary immune responses. J Immunol. 1999;163:4315-4327.
36. West DJ, Calandra GB. Vaccine induced immunologic memory for hepatitis B surface antigen: implications for policy on booster vaccination. Vaccine. 1996;14:1019-1027.
37. Banatvala J, Van Damme P, Oehen S. Lifelong protection against hepatitis B: the role of vaccine immunogenicity in immune memory. Vaccine. 2000;19:877-885.
38. Bachmann MF, Odermatt B, Hengartner H, Zinkernagel RM. Induction of long-lived germinal centers associated with persisting antigen after viral infection. J Exp Med. 1996;183:2259-2269.
39. Kwon SY, Lee CH. Epidemiology and prevention of hepatitis B virus infection. Korean J Hepatol. 2011;17:87-95. https://doi.org/10.3350/kjhep.2011.17.2.87
40. Kroger AT, Sumaya CV, Pickering LK, Atkinson WL. General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). Morb Mortal Wkly Rep Recomm Rep. 2011;1-60.
41. Averhoff F, Mahoney F, Coleman P, Schatz G, Hurwitz E, Margolis H. Immunogenicity of hepatitis B vaccines: implications for persons at occupational risk of hepatitis B virus infection. Am J Prev Med. 1998;15:1-8.
42. Yang S, Tian G, Cui Y, et al. Factors influencing immunologic response to hepatitis B vaccine in adults. Sci Rep. 2016;6:27251. https://doi.org/10.1038/srep27251
43. Keeffe EB, Krause DS. Hepatitis B vaccination of patients with chronic liver disease. Liver Transpl Surg. 1998;4:437-439.
44. Alter MJ. Vaccinating patients with chronic liver disease. Gastroenterology & Hepatology. 2012;8:120-122.
45. Pascasio JM, Aoufi S, Gash A, et al. Response to a vaccination schedule with 4 doses of 40 μg against hepatitis B virus in cirrhotic patients evaluated for liver transplantation. Transplant Proc. 2008;40:2943-2945. https://doi.org/10.1016/j.transproceed.2008.09.029
46. Hadler SC, Margolis HS. Hepatitis B immunization: vaccine types, efficacy, and indications for immunization. Curr Clin Top Infect Dis. 1992;12:282-308.
47. Jan CF, Huang KC, Chien YC, et al. Determination of immune memory to hepatitis B vaccination through early booster response in college students. Hepatology. 2010;51:1547-1554. https://doi.org/10.1002/hep.23543
48. Idilman R, Colantoni A, De Maria N, et al. Impaired antibody response rates after high dose short interval hepatitis B virus vaccination of immunosuppressed individuals. Hepatogastroenterology. 2003;50:217-221.
49. Fonseca MO, Pang LW, de Paula CN, Barone AA, Heloisa LM. Randomized trial of recombinant hepatitis B vaccine in HIV-infected adult patients comparing a standard dose to a double dose. Vaccine. 2005;23:2902-2908. https://doi.org/10.1016/j.vaccine.2004.11.057
50. Zuckerman JN. Protective efficacy, immunotherapeutic potential, and safety of hepatitis B vaccines. J Med Virol. 2006;78:169-177. https://doi.org/10.1002/jmv.20524
51. Andre FE. Summary of safety and efficacy data on a yeast-derived hepatitis B vaccine. Am J Med. 1989;87:14S-20S.
52. Nevens F, Zuckerman JN, Burroughs AK, et al. Immunogenicity and safety of an experimental adjuvanted hepatitis B candidate vaccine in liver transplant patients. Liver Transpl. 2006;12:1489-1495. https://doi.org/10.1002/lt.20836
53. Chen DS. Hepatitis B vaccination: the key towards elimination and eradication of hepatitis B. J Hepatol. 2009;50:805-816. https://doi.org/10.1016/j.jhep.2009.01.002
54. Schirren CA, Jung MC, Zachoval R, et al. Analysis of T cell activation pathways in patients with liver cirrhosis, impaired delayed hypersensitivity and other T cell-dependent functions. Clin Exp Immunol. 1997;108:144-150.
55. Egea E, Iglesias A, Salazar M, et al. The cellular basis for lack of antibody response to hepatitis B vaccine in humans. J Exp Med. 1991;173:531-538.
56. Godkin A, Davenport M, Hill AV. Molecular analysis of HLA class II associations with hepatitis B virus clearance and vaccine nonresponsiveness. Hepatology. 2005;41:1383-1390. https://doi.org/10.1002/hep.20716
57. Jafarzadeh A, Bagheri-Jamebozorgi M, Nemati M, Golsaz-Shirazi F, Shokri F. Human leukocyte antigens influence the antibody response to hepatitis B vaccine. Iran J Allergy Asthma Immunol. 2015;14:233-245.
58. Hui CK, Lau GK. Advances in immunomodulating therapy of HBV infection. Int J Med Sci. 2005;2:24-29.
59. Ito H, Ando T, Nakamura M, et al. Induction of humoral and cellular immune response to hepatitis B virus (HBV) vaccine can be upregulated by CpG oligonucleotides complexed with Dectin-1 ligand. J Viral Hepat. 2016.
60. Koff RS. Immunogenicity of hepatitis B vaccines: implications of immune memory. Vaccine. 2002;20:3695-3701.
61. Flacher V, Bouschbacher M, Verronese E, et al. Human Langerhans cells express a specific TLR profile and differentially respond to viruses and gram-positive bacteria. J Immunol. 2006;177:7959-7967.
62. Nicolas JF, Guy B. Intradermal, epidermal and transcutaneous vaccination: from immunology to clinical practice. Expert Rev Vaccines. 2008;7:1201-1214. https://doi.org/10.1586/14760584.7.8.1201
63. Lambert PH, Laurent PE. Intradermal vaccine delivery: will new delivery systems transform vaccine administration? Vaccine. 2008;26:3197-3208. https://doi.org/10.1016/j.vaccine.2008.03.095
64. Filippelli M, Lionetti E, Gennaro A, et al. Hepatitis B vaccine by intradermal route in non responder patients: an update. World J Gastroenterol. 2014;20:10383-10394. https://doi.org/10.3748/wjg.v20.i30.10383